encroachment across 5' or 3' CpG island borders. CpG island methylation encroachment is a widespread phenomenon in clinical prostate and breast cancer and is commonly associated with gene suppression. By integrating whole-genome DNA methylation sequencing and chromatin modification sequencing data, we have revealed that the pattern of histone lysine 4 monomethylated (H3K4me1) nucleosomes in normal cells is associated with the different modes of CpG island hypermethylation. Notably, we show that genetic manipulation of lysine histone methyltransferase 2D (KMT2D) results in concordant alterations in H3K4me1 levels and corresponding CpG island border DNA methylation encroachment. Prostate cancer DNA harbouring KMT2D mutations also display reduced erosion of CpG island border methylation. Our findings establish a unique role for H3K4me1 in the demarcation of CpG island borders in normal cells, which become eroded in cancer.¹

Reference

1. Skvortsova K, Masle-Farquhar E, Luu P-L, *et al.* DNA hypermethylation encroachment at CpG island borders in cancer is predisposed by H3K4 monomethylation patterns. *Cancer Cell* 2019; 35: 297-314.e8.

MOLECULAR PROFILING IN HAEMATOLOGICAL MALIGNANCIES – THE MOST-LLY STUDY

Steven Lane^{1,2}

¹QIMR Berghofer, Gordon and Jessie Gilmour Leukaemia Research Laboratory, QIMR Berghofer, Herston, Qld, Australia; and ²Royal Brisbane and Women's Hospital, Herston, Qld, Australia

MoST-LLy (Molecular Screening and Therapeutics in Leukaemia and Lymphoma) has a unique study design with molecular screening using Illumina's TruSight™ Oncology 500 Next Generation Sequencing (NGS) assay, and linking patients with advanced haematological malignancy with no standard of care treatment, to access targeted clinical trials and treatments they would otherwise not have access to.

The overarching MoST framework protocol governs molecular screening with each substudy reviewed and approved as an addenda to the program. We have developed two novel haematology specific treatment substudies with pharma that will soon open to recruitment, including:

- MoST 15: durvalumab + acalabrutinib for high-grade B cell lymphoma.
- MoST 16: PARP inhibitor for relapsed/refractory myeloid haematological malignancy.

MoST-LLy is the first molecular screening of its kind in blood cancers in Australia, and is being piloted across two sites initially with funding provided by the Leukemia Foundation of Australia and Tour de Cure to screen 240 patients, with plans to roll out nationally.

GENETIC TESTING FOR FAMILIAL HYPERCHOLESTEROLAEMIA

John R. Burnett^{1,2}

¹Department of Clinical Biochemistry, PathWest Laboratory Medicine, Royal Perth Hospital and Fiona Stanley Hospital Network, Perth, WA, Australia; and ²School of Medicine, University of Western Australia, Nedlands, WA, Australia

Familial hypercholesterolaemia (FH) is a codominant genetic disorder causing premature atherosclerotic cardiovascular disease (ASCVD). It is common, affecting 1 in 250 individuals worldwide and of the ~100,000 Australians estimated to have FH, most are undiagnosed and treatment is often suboptimal. Several scoring algorithms based on low-density lipoprotein-cholesterol (LDL-C) levels, physical findings, and elements of personal and family history, help clinicians diagnose FH at varying levels of confidence ranging from possible to definite. Targeted DNA sequencing to identify the underlying pathogenic variant in any of the three FH genes (*LDLR*, *APOB*, and *PCSK9*) has become more accessible, but it is not essential for diagnosis of FH, and is currently not widely used. However, identification of a pathogenic variant is considered the 'gold standard' for FH diagnosis. Expanded FH panels can identify pathogenic variants in other hypercholesterolaemia genes, such as *APOE*, *LIPA*, and *ABCG5/8*. FH cascade screening is recommended to identify affected family members, and the benefits of early intervention to lower LDL-C and reduce the associated ASCVD burden are clear. National registries can also play a key role in identifying patients with FH. FH genetic testing should be incorporated as standard of care for patients and their relatives with suspected FH.

THE ONCOGENE AND COAGULOME

Kate Burbury^{1,2}

¹Department of Haematology, Peter MacCallum Cancer Centre, Melbourne Health, Vic, Australia; and ²University of Melbourne, Vic, Australia

Cancer is the second-leading cause of death globally, predominantly due to metastasis – the escape of tumour cells from their initial to a distant site. Importantly, thromboembolism associated with cancer is the second-leading cause of cancer mortality, and in non-fatal events, a major contributor to morbidity, interruption to therapy and healthcare resource utilisation. Adding to the complexity, patients with cancer are also at high risk of haemorrhagic events during the course of their disease and treatment. Further understanding of haemostatic dysregulation is a significant unmet need in oncology. The pathogenesis is complex and involves the interplay of multiple factors. However, there is growing evidence that interactions between malignancies and the coagulation system are not random but represent coordinated and clinically-significant adaptations that enhance tumour cell survival, proliferation and metastatic potential. Hence understanding the interactions between haemostatic systems, vascular stroma and metastasis may not only provide insight into strategies that could potentially reduce the incidence of thrombohaemorrhagic events, but also help design strategies that are capable of modifying tumour biology and metastatic potential, and thereby improve overall survival. This presentation will provide an overview of biological and clinical evidence linking oncogenic signalling and coagulation phenotypes, and the opportunity for impact.

MATCHING TARGET TO THERAPY IN CHILDHOOD CANCERS

Paul Ekert

Translational Tumor Biology, Children's Cancer Institute, Randwick, NSW, Australia